Last reviewed · How we verify

NCT04461613

Physical Activity in Persons With Charcot-Marie-Tooth: Developing a Measurement Instrument

Status unknown NA Last updated 24 February 2021
What this trial tests

NA trial testing Original IPAQ followed by a revised one. in Hereditary Motor and Sensory Neuropathy in 20 participants. Status unknown.

Timeline
15 September 2020
Primary endpoint
31 March 2021
30 April 2021

Quick facts

Lead sponsorOslo University Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposescreening
Enrollment20
Start date15 September 2020
Primary completion31 March 2021
Estimated completion30 April 2021
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Oslo University Hospital

Who can join

Adults 18 to 65, any sex, with Hereditary Motor and Sensory Neuropathy or Charcot-Marie-Tooth. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project will develop knowledge about physical activity in persons with Charcot-Marie-Tooth (CMT) in Norway. We plan to explore instruments to measure physical activity level for the target-group at the community level. We want to understand which type of activities, activity intensities and how persons with CMT perform habitual physical activity. Subsequently, a physical activity measurement instrument adapted to persons with CMT will be developed. This instrument can be used in a future intervention project to promote physical activity in this group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Oslo University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04461613.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing